{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dalfampridine%2FPlacebo&page=2",
    "query": {
      "intervention": "Dalfampridine/Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 38,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dalfampridine%2FPlacebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dalfampridine%2FPlacebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T06:27:53.417Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01356940",
      "title": "A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dalfampridine ER",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown, Theodore R., M.D., MPH",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-11",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2018-10-31",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 1,
      "location_summary": "Kirkland, Washington",
      "locations": [
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01356940"
    },
    {
      "nct_id": "NCT02166346",
      "title": "Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transverse Myelitis",
        "Neuromyelitis Optica",
        "Idiopathic Transverse Myelitis",
        "Myelitis NOS"
      ],
      "interventions": [
        {
          "name": "Dalfampridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-02",
      "completion_date": "2017-01-08",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02166346"
    },
    {
      "nct_id": "NCT02562066",
      "title": "Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myasthenic Syndromes, Congenital"
      ],
      "interventions": [
        {
          "name": "amifampridine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-01",
      "completion_date": "2019-10",
      "has_results": true,
      "last_update_posted_date": "2021-04-02",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02562066"
    },
    {
      "nct_id": "NCT01605825",
      "title": "A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "placebo/dalfampridine-ER",
          "type": "DRUG"
        },
        {
          "name": "dalfampridine-ER/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 83,
      "start_date": "2012-05",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2016-01-22",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Newport Beach, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605825"
    },
    {
      "nct_id": "NCT06853015",
      "title": "Double Dose 4-AP on Functional Recovery After Spinal Cord Injury",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SCI - Spinal Cord Injury"
      ],
      "interventions": [
        {
          "name": "Dalfampridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "STDP stimulation",
          "type": "OTHER"
        },
        {
          "name": "Exercise training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Shirley Ryan AbilityLab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-02-01",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06853015"
    },
    {
      "nct_id": "NCT02219932",
      "title": "Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "fampridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 646,
      "start_date": "2014-09",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-03-27",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 17,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02219932"
    },
    {
      "nct_id": "NCT04026568",
      "title": "A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Nerve Injury"
      ],
      "interventions": [
        {
          "name": "4-Aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-08-17",
      "completion_date": "2022-07-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04026568"
    },
    {
      "nct_id": "NCT06596434",
      "title": "4-Aminopyridine to Treat Skin Burns",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Burns",
        "Second Degree Burn",
        "Wounds and Injuries"
      ],
      "interventions": [
        {
          "name": "Drug: 4-Aminopyridine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "John Elfar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2026-01-01",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06596434"
    },
    {
      "nct_id": "NCT01377922",
      "title": "A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lambert Eaton Myasthenic Syndrome"
      ],
      "interventions": [
        {
          "name": "Amifampridine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Catalyst Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2011-06",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01377922"
    },
    {
      "nct_id": "NCT01328379",
      "title": "Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Dalfampridine-ER 5mg",
          "type": "DRUG"
        },
        {
          "name": "Dalfampridine-ER 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 430,
      "start_date": "2011-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-10-02T06:27:53.417Z",
      "location_count": 70,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01328379"
    }
  ]
}